---
title: 'Life Sciences Daily Summary: What Happened on November 19, 2026'
headline: FDA approves Lembaz to reduce mortality risk in eligible Niemann-Pick patients
description: A retrospective study found that enterocolitis after CAR T therapy for
  multiple myeloma was active when some patients died. The day also brought another
  FDA approval, a proposed UK rule change, and new biotech financing and dealmaking.
url: https://thebench.bio/news/summaries/2026-11-19
topic: all
date: '2026-11-19'
covers:
- '2026-11-19'
date_published: '2026-11-19T12:05:55Z'
date_modified: '2026-11-19T12:05:55Z'
tags:
- Industry
- Regulatory
sources: 12
publisher: TheBench.Bio
---

# Life Sciences Daily Summary: What Happened on November 19, 2026

**FDA approves Lembaz to reduce mortality risk in eligible Niemann-Pick patients**

A retrospective study found that enterocolitis after CAR T therapy for multiple myeloma was active when some patients died. The day also brought another FDA approval, a proposed UK rule change, and new biotech financing and dealmaking.

## Today in brief

The FDA approved Beren's Lembaz for adults and children with infantile-onset Niemann-Pick disease type C who meet weight and age-of-onset criteria. [1] A multicenter study identified enterocolitis in 41 patients treated with cilta-cel for multiple myeloma. Seventeen died while the condition was active. [2]

Regeneron's Livsayis won FDA approval for adults with antibody-positive generalized myasthenia gravis. The UK proposed broadening its legal definition of gene therapy medicines. [3] [4] Seawolf launched with $100 million in financing and a Sanofi collaboration. AbbVie agreed to pay DISCO Pharmaceuticals $40 million upfront in a cancer drug discovery deal. [5] [6]

## Lembaz approved for eligible patients with Niemann-Pick disease

The FDA approved Beren's Lembaz, or adrabetadex, to reduce mortality risk in adults and children who weigh at least 7 kilograms and whose neurological symptoms began before age 6. [1] In an analysis of 36 treated patients, mortality risk was 55% lower than among matched external controls. [1]

Diagnosing the disease can take years. Beren now needs to identify patients who may qualify for treatment. [1]

## Study finds severe, sometimes fatal enterocolitis after cilta-cel

A multicenter retrospective study classified 41 of 53 evaluable suspected cases as immune effector cell-associated enterocolitis after ciltacabtagene autoleucel, or cilta-cel, treatment for multiple myeloma. [2] Tissue testing confirmed 31 cases, while researchers considered 10 probable. [2] The estimated cumulative rate was 3.0% among 1,308 cilta-cel recipients included in the incidence calculation. The authors cautioned that the referral-based estimate may not reflect the broader treated population. [2]

Symptoms began a median of 75 days after infusion. Of 40 patients with diarrhea, 34 had severe symptoms. [2] At last follow-up, 13 patients had recovered, 11 still had symptoms, and 17 had died while enterocolitis remained active. [2] A separate MD Anderson cohort found nine cases among 158 cilta-cel recipients. Affected patients had 100 times greater CAR T-cell persistence than patients without the condition. [7]

## Livsayis wins FDA approval for antibody-positive myasthenia gravis

The FDA approved Regeneron's Livsayis for adults with generalized myasthenia gravis who test positive for anti-AChR antibodies. [3] The siRNA treatment is injected under the skin four times a year. It is designed to lower circulating factor 5 and reduce terminal complement activation. [3]

In the Phase 3 NIMBLE trial, patients improved 4.5 points on a daily-living scale at week 24, compared with 2.2 points on placebo. The 2.3-point difference was statistically significant. [3] The most common adverse reactions, each reported in at least 5% of patients, were injection-site reactions, urinary tract infections, and viral infections. [3] European Union regulators are reviewing the drug, with a decision expected in late 2027. [3]

## UK proposes broader legal definition of gene therapy medicines

The UK government proposed revising the legal definition of gene therapy medicines to bring certain synthetic therapies and genome-editing treatments into the existing advanced therapies framework. [4] The government says the revision would clarify classification and regulatory requirements without changing approval standards or requiring licensed medicines to be reclassified. [4]

The proposal would amend the Human Medicines Regulations 2012 and requires international notification procedures and parliamentary approval. [4] The consultation received support from 83% of respondents. [4]

## Seawolf launches with $100 million and a Sanofi collaboration

Seawolf emerged from stealth with $100 million in seed and Series A financing and an upfront payment from Sanofi under a collaboration. [5] Its TRIDENT platform puts therapeutic DNA and RNA, encoding a protein intended to help DNA enter the cell nucleus, into one lipid nanoparticle. [5]

The company aims to pair the durability of viral gene therapies with the ability to redose RNA-based lipid nanoparticles, while limiting immune responses that could prevent repeat dosing. [5]

## AbbVie offers DISCO up to $2.5 billion for cancer discovery programs

AbbVie will pay DISCO Pharmaceuticals $40 million upfront to discover cancer drugs. DISCO could receive up to $2.5 billion more in option, development, and other milestone payments, plus tiered royalties. [6] DISCO will conduct research, after which AbbVie may take exclusive licenses to selected programs. [6]

DISCO's platform searches for pairs of surface proteins found together more often on cancer cells than on healthy tissue. [6]

## Johnson & Johnson agrees to buy Ollin for up to $3.325 billion

On November 16, Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront and up to $1.125 billion in regulatory and commercial milestone payments. [8] Ollin's lead drug, OLN324, is an investigational bispecific antibody in Phase 3 development for retinal diseases, including wet age-related macular degeneration and diabetic macular edema. [8]

Johnson & Johnson also announced a $750 million development-financing arrangement with Blackstone Life Sciences, with contingent payments and royalties. [8]

## White House withdraws Overton's FDA nomination

On November 17, the White House withdrew Heidi Overton's nomination to lead the FDA, the night before a Senate committee was scheduled to consider it. [9] [10] Three sources cited by Reuters said the nomination lacked enough congressional support. Senator Bill Cassidy said he believed Overton had enough votes to advance. [9] [10]

Kyle Diamantas continues to lead the agency in an acting capacity. [9] The FDA expects to finish its review of mifepristone's safety by March 2027. [9]

## FDA approves Infilbray for neurological symptoms of Type 3 Gaucher disease

On November 18, the FDA approved Infilbray for neurological symptoms of Type 3 Gaucher disease in adults and children weighing at least 15 kilograms. [11] The drug crosses the blood-brain barrier and inhibits an enzyme involved in the buildup of harmful substances. [11]

In a 43-person study, patients taking Infilbray improved on a combined measure of coordination and cognitive function at week 52 compared with patients receiving enzyme replacement therapy. [11] Reported risks include gastrointestinal and mood effects, suicidal thoughts and behavior, possible vision clouding in younger patients, and potential fetal-development harm during pregnancy. [11]

## California biopharma layoffs reach at least 1,176 workers

A BioSpace tally found that 24 California biopharma companies had made or projected cuts affecting at least 1,176 workers this year. [12] Nine companies were cutting at least half their workforces, and two had closed. [12]

Among the listed cuts, Arsenal Biosciences said it would eliminate 99 positions, while Caribou Biosciences' layoff notice listed 87 jobs. [12] Artiva Biotherapeutics said it would cut about 94% of its staff after stopping development of its lead candidate. [12]

## The day in numbers

- **55%**: Lower mortality risk in Lembaz-treated patients than in matched external controls in a 36-patient analysis. [1]
- **17 of 41**: Patients with enterocolitis who died while the condition was active at last follow-up. [2]
- **$100 million**: Seed and Series A financing raised by Seawolf. [5]
- **$2.5 billion**: Maximum potential milestone payments in DISCO's AbbVie agreement, in addition to $40 million upfront and royalties. [6]
- **1,176**: Minimum number of workers affected by reported or projected California biopharma cuts this year. [12]

## Sources

1. [With Lembaz approved, Beren turns to diagnosis and patient access](<https://www.biocentury.com/article/661663/with-lembaz-approved-beren-turns-to-diagnosis-and-patient-access?utm_source=bc_rss&utm_medium=rss>), BioCentury, 2026-11-19
2. [Multicenter characterization of enterocolitis associated with BCMA-directed CAR T cell therapy](<https://www.nature.com/articles/s41591-026-04783-y>), Nature Medicine, 2026-11-19
3. [FDA approves Regeneron’s Livsayis for generalised myasthenia gravis](<https://www.pharmaceutical-technology.com/news/fda-regenerons-livsayis-generalised-myasthenia-gravis/>), Pharmaceutical Technology, 2026-11-19
4. [Government backs modernisation of gene therapy definitions](<https://www.gov.uk/government/news/government-backs-modernisation-of-gene-therapy-definitions>), MHRA, 2026-11-19
5. [Seawolf: Making DNA durable, redosable, and able to enter the nucleus](<https://www.biocentury.com/article/661617/seawolf-making-dna-durable-redosable-and-able-to-enter-the-nucleus?utm_source=bc_rss&utm_medium=rss>), BioCentury, 2026-11-19
6. [After Amgen, DISCO lands AbbVie deal worth up to $2.5B](<https://european-biotechnology.com/latest-news/after-amgen-disco-lands-abbvie-deal-worth-up-to-2-5b/>), European Biotechnology, 2026-11-19
7. [Expansion and cytotoxicity of mucosal CAR\<sup\>+\</sup\> T cells in enterocolitis associated with BCMA CAR-T cell therapy](<https://www.nature.com/articles/s41591-026-04731-w>), Nature Medicine, 2026-11-19
8. [Johnson & Johnson's Strategic Shift: Why Diversification Is Giving Way to Focus](<https://www.pharmexec.com/view/pharmaceutical-company-strategy-johnson-johnson-diversification>), Pharmaceutical Executive, 2026-11-19
9. [Trump Pulls Overton's FDA Nomination Ahead of Senate HELP Vote](<https://www.pharmaceuticalcommerce.com/view/trump-pulls-overton-s-fda-nomination-ahead-of-senate-help-vote>), Pharmaceutical Commerce, 2026-11-18
10. [White House Withdraws Dr. Heidi Overton’s Nomination as FDA Commissioner: Report](<https://www.pharmexec.com/view/white-house-withdraws-dr-heidi-overton-nomination-fda-commissioner-report>), Pharmaceutical Executive, 2026-11-18
11. [FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease](<http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease>), FDA Press Announcements, 2026-11-18
12. [9 biotechs will cut at least half their California workforces](<https://www.biospace.com/job-trends/9-biotechs-will-cut-at-least-half-their-california-workforces>), BioSpace, 2026-11-19

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.biocentury.com/article/661663/with-lembaz-approved-beren-turns-to-diagnosis-and-patient-access?utm_source=bc_rss&utm_medium=rss>
[2]: <https://www.nature.com/articles/s41591-026-04783-y>
[3]: <https://www.pharmaceutical-technology.com/news/fda-regenerons-livsayis-generalised-myasthenia-gravis/>
[4]: <https://www.gov.uk/government/news/government-backs-modernisation-of-gene-therapy-definitions>
[5]: <https://www.biocentury.com/article/661617/seawolf-making-dna-durable-redosable-and-able-to-enter-the-nucleus?utm_source=bc_rss&utm_medium=rss>
[6]: <https://european-biotechnology.com/latest-news/after-amgen-disco-lands-abbvie-deal-worth-up-to-2-5b/>
[7]: <https://www.nature.com/articles/s41591-026-04731-w>
[8]: <https://www.pharmexec.com/view/pharmaceutical-company-strategy-johnson-johnson-diversification>
[9]: <https://www.pharmaceuticalcommerce.com/view/trump-pulls-overton-s-fda-nomination-ahead-of-senate-help-vote>
[10]: <https://www.pharmexec.com/view/white-house-withdraws-dr-heidi-overton-nomination-fda-commissioner-report>
[11]: <http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease>
[12]: <https://www.biospace.com/job-trends/9-biotechs-will-cut-at-least-half-their-california-workforces>
